APA

Gadgeel S. M., Ruckdeschel J. C., Heath E. I., Heilbrun L. K., Venkatramanamoorthy R. & Wozniak A. (20070501). Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chicago

Gadgeel Shirish M, Ruckdeschel John C, Heath Elisabeth I, Heilbrun Lance K, Venkatramanamoorthy Raghu and Wozniak Antoinette. 20070501. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harvard

Gadgeel S. M., Ruckdeschel J. C., Heath E. I., Heilbrun L. K., Venkatramanamoorthy R. and Wozniak A. (20070501). Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MLA

Gadgeel Shirish M, Ruckdeschel John C, Heath Elisabeth I, Heilbrun Lance K, Venkatramanamoorthy Raghu and Wozniak Antoinette. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 20070501.